Prestige Consumer Healthcare Inc. (PBH)
| Market Cap | 2.28B -45.3% |
| Revenue (ttm) | 1.09B -4.3% |
| Net Income | 190.30M -11.3% |
| EPS | 3.91 -8.9% |
| Shares Out | 47.37M |
| PE Ratio | 12.23 |
| Forward PE | 10.38 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,221 |
| Open | 47.63 |
| Previous Close | 47.82 |
| Day's Range | 46.77 - 49.50 |
| 52-Week Range | 42.62 - 85.57 |
| Beta | 0.35 |
| Analysts | Buy |
| Price Target | 66.80 (+38.59%) |
| Earnings Date | May 13, 2026 |
About PBH
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mo... [Read more]
Financial Performance
In fiscal year 2026, PBH's revenue was $1.09 billion, a decrease of -4.31% compared to the previous year's $1.14 billion. Earnings were $190.30 million, a decrease of -11.32%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for PBH stock is "Buy." The 12-month stock price target is $66.8, which is an increase of 38.59% from the latest price.
News
Prestige Consumer Healthcare Transcript: Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference
The session highlighted a disciplined strategy focused on brand leadership, stable growth, and capital allocation, with recent major acquisitions (Breathe Right, LaCorium Health) expected to drive above-average growth. Consumer shifts favor mass and e-commerce, while operational improvements and international expansion underpin a positive outlook.
Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference
TARRYTOWN, N.Y., June 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Grow...
Prestige Consumer price target lowered to $72 from $86 at Canaccord
Canaccord lowered the firm’s price target on Prestige Consumer (PBH) to $72 from $86 and keeps a Buy rating on the shares. The firm updated its model following its Q4…
Prestige Consumer falls -14.0%
Prestige Consumer (PBH) is down -14.0%, or -$7.25 to $44.56.
Oppenheimer downgrades Prestige Consumer following weaker results, guidance
As previously reported, Oppenheimer analyst Rupesh Parikh downgraded Prestige Consumer (PBH) to Perform from Outperform following the company’s softer than expected Q4 results and weaker initial FY26 ...
Prestige Consumer Healthcare Earnings Call Transcript: Q4 2026
Fiscal 2026 saw a 4% revenue decline due to eye care supply issues and global disruptions, but GI and women's health brands performed well. Fiscal 2027 guidance anticipates 1%-3% organic growth, stable margins, and strong free cash flow, with pending acquisitions expected to drive future growth.
Prestige Consumer Healthcare Earnings release: Q4 2026
Prestige Consumer Healthcare released its Q4 2026 earnings on May 14, 2026, summarizing the period's financial results.
Prestige Consumer Healthcare Slides: Q4 2026
Prestige Consumer Healthcare has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 14, 2026.
Prestige Consumer Healthcare Annual report: Q4 2026
Prestige Consumer Healthcare has published its Q4 2026 annual report on May 14, 2026.
Prestige Consumer downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Prestige Consumer (PBH) to Perform from Outperform.
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health
TARRYTOWN, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2026.
Prestige Consumer price target lowered to $65 from $77 at Oppenheimer
Oppenheimer analyst Rupesh Parikh lowered the firm’s price target on Prestige Consumer (PBH) to $65 from $77 and keeps an Outperform rating on the shares. The firm notes the company…
Prestige Consumer Healthcare to Release Fiscal 2026 Fourth Quarter and Year-End Earnings Results
TARRYTOWN, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 fourth quarter and year-end earnings release on Wedn...
Prestige Consumer Healthcare to Buy Breathe Right, Other Brands for $1.045 Billion
Prestige signed a deal to buy a portfolio of brands that includes the Breathe Right nasal strip from privately held Foundation Consumer Healthcare.
Prestige Consumer Healthcare Transcript: M&A announcement
The acquisition of a portfolio led by Breathe Right for $1.045 billion is expected to add 20% to revenue, be immediately accretive to margins and EPS, and double international presence, with limited synergies but strong long-term growth prospects and tax benefits.
Prestige Consumer Healthcare Press release: M&A announcement
Prestige Consumer Healthcare issued a press release on March 20, 2026, disclosing material business information to investors.
Prestige Consumer Healthcare Slides: M&A announcement
Prestige Consumer Healthcare has posted slides in relation to its latest quarterly earnings report, which was published on March 20, 2026.
Prestige Consumer to acquire Breathe Right, other brands for $1.045B
Prestige Consumer (PBH) Healthcare has entered into a definitive agreement to acquire the Breathe Right brand and certain other brands from Foundation Consumer Healthcare for $1.045B, or approximately...
Prestige Consumer Healthcare Announces Agreement to Acquire Breathe Right®, the Leader in Nasal Strips
TARRYTOWN, N.Y., March 20, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (the “Company” or “Prestige”) (NYSE: PBH) today announced that it has entered into a definitive agreement to acqui...
Prestige Consumer price target lowered to $86 from $88 at Canaccord
Canaccord lowered the firm’s price target on Prestige Consumer (PBH) to $86 from $88 and keeps a Buy rating on the shares. The firm said they reported 3Q26 results with…
Prestige Consumer Healthcare Earnings Call Transcript: Q3 2026
Q3 revenue declined 2.4% year-over-year to $283.4 million, mainly due to Clear Eyes supply constraints, but strong free cash flow and e-commerce growth offset category softness. Fiscal 2026 guidance was narrowed, with EPS expected at $4.54 and free cash flow at $245 million or more.
Prestige Consumer Healthcare Quarterly report: Q3 2026
Prestige Consumer Healthcare has published its Q3 2026 quarterly earnings report on February 5, 2026.
Prestige Consumer Healthcare Earnings release: Q3 2026
Prestige Consumer Healthcare released its Q3 2026 earnings on February 5, 2026, summarizing the period's financial results.
Prestige Consumer Healthcare Slides: Q3 2026
Prestige Consumer Healthcare has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 5, 2026.
Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results
TARRYTOWN, N.Y., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third quarter and nine months ended December 31, 2025.